Skip to main content
OpenTrials
Completed

NCT Number: NCT06988969

Predicting Vaccine Hesitancy Using Machine Learning

In recent years, emerging technologies such as the Internet of Things (IoT), Artificial Intelligence (AI), and Virtual Reality (VR) have rapidly become integrated into daily life. The widespread use of these applications has led to the accumulation of vast amounts of data, giving rise to what is commonly referred to as "Big Data." Due to the sheer volume, manual processing and analysis of these large datasets are not feasible. Therefore, software tools and libraries-such as Python and R libraries-have been developed to perform these analyses efficiently and to generate predictions for the future by leveraging historical data through Machine Learning (ML) algorithms.

The primary goal of machine learning algorithms is to discover patterns within existing data and use these patterns to make accurate predictions on new data. The use of machine learning in the field of healthcare has gained significant momentum in recent years. However, a review of the literature reveals that research specifically addressing childhood vaccine hesitancy remains limited.

This study aims to identify the factors contributing to vaccine hesitancy among parents of children aged 0-48 months and to develop a predictive model using machine learning techniques based on these factors. Such a model could help anticipate the likelihood of vaccine refusal among parents and thereby support the development of targeted public health strategies for at-risk populations.

Completed

Looking for future studies?

Notify Me

Key information

Age range

18 year–65 year

Sex eligibility

All sexes

Study type

Observational

Primary location

Yalova University

Yalova, 77200, Turkey (Türkiye)

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Parents who meet the following criteria will be included in the study:

  • Have proficiency in understanding and reading the Turkish language,
  • Are able to use technological devices such as mobile phones or computers to access social media platforms (Participants used social media platforms such as Instagram and WhatsApp to communicate) via the internet,
  • Are 18 years of age or older,
  • Have children aged 0-4 years,
  • Consent to participate in the study,
  • Have children without any absolute contraindications to vaccination.

Exclusion criteria

  • Parents of high-risk infants (such as those with a history of systemic illness, preterm labor, anomalies, etc.),
  • Parents who are unwilling to participate in the study will be excluded.

Treatment and study plan

Primary outcomes

  1. Parental Vaccine Hesitancy Status

    Time frame: Day 1 (Parents will be sent the questionnaire and asked to respond promptly.)

    The Vaccine Hesitancy Scale is a measurement tool designed to assess individuals' vaccine hesitancy or opposition. It consists of 21 items across 4 subscales and uses a 5-point Likert scale format. The four subscales of the scale are: Vaccine Benefit and Protective Value, Vaccine Opposition, Solutions for Avoiding Vaccination, and Justification of Vaccine Hesitancy. Higher scores on the scale indicate greater levels of vaccine hesitancy or opposition.

Sponsors and collaborators

Lead sponsor

University of Yalova

Other

Registry information

Official study title

Factors Influencing Vaccine Hesitancy Among Parents of Children Aged 0-48 Months: A Machine Learning Prediction

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
May 25, 2025
Registry last updated
Jul 14, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.